Skip to main content
Top
Published in: Diagnostic Pathology 1/2013

Open Access 01-12-2013 | Case Report

Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma – a case report

Authors: Barrett Parker Wagner, Narendranath Epperla, Rafael Medina-Flores

Published in: Diagnostic Pathology | Issue 1/2013

Login to get access

Abstract

Clear cell sarcoma is a rare cancer primarily of tendons, fascia, and aponeuroses that can be difficult to discern from primary cutaneous malignant melanoma. The two cancers share several histological markers, with most cases of both cancers staining positively for S-100, HMB-45, and melanin. Primary therapy of both cancers involves wide local excision, but while systemic therapy has proven benefit for malignant melanoma, it has not been established for clear cell sarcoma.
We report the case of a 58 year old woman with a large, ulcerated, fungating mass on her left lower leg. Frozen section of the mass showed a malignant epithelioid and spindle cell tumor confined to the subcutaneous tissue. A provisional diagnosis of soft-tissue sarcoma was made. Through in-depth study of initial biopsy with immunohistochemistry for S-100, HMB-45, MART-1, and MITF, along with karyotyping and FISH analysis for EWS gene rearrangement, the diagnosis of amelanotic malignant melanoma was confirmed. The patient then underwent systemic treatment with ipilimumab upon recurrence with good response.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​1989338475107348​.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ: Early detection and treatment of skin cancer. Am Fam Physician. 2000, 62 (2): 357-68. 375–6, 381–2PubMed Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ: Early detection and treatment of skin cancer. Am Fam Physician. 2000, 62 (2): 357-68. 375–6, 381–2PubMed
2.
go back to reference James WD, Berger TG, Elston DM: Andrew's Diseases of the Skin: Clinical Dermatology. 2011, Philadelphia: Elsevier/Saunders, 11 James WD, Berger TG, Elston DM: Andrew's Diseases of the Skin: Clinical Dermatology. 2011, Philadelphia: Elsevier/Saunders, 11
3.
go back to reference Malchau SS, Hayden J, Hornicek F, Mankin HJ: Clear cell sarcoma of soft tissues. J Surg Oncol. 2007, 95 (6): 519-522. 10.1002/jso.20730.CrossRefPubMed Malchau SS, Hayden J, Hornicek F, Mankin HJ: Clear cell sarcoma of soft tissues. J Surg Oncol. 2007, 95 (6): 519-522. 10.1002/jso.20730.CrossRefPubMed
4.
go back to reference Chung EB, Enzinger FM: Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Am J Surg Pathol. 1983, 7 (5): 405-413. 10.1097/00000478-198307000-00003.CrossRefPubMed Chung EB, Enzinger FM: Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Am J Surg Pathol. 1983, 7 (5): 405-413. 10.1097/00000478-198307000-00003.CrossRefPubMed
5.
go back to reference Dim DC, Cooley LD, Miranda RN: Clear cell sarcoma of tendons and aponeuroses: a review. Arch Pathol Lab Med. 2007, 131: 152-156.PubMed Dim DC, Cooley LD, Miranda RN: Clear cell sarcoma of tendons and aponeuroses: a review. Arch Pathol Lab Med. 2007, 131: 152-156.PubMed
6.
go back to reference American Cancer Society: Cancer Facts & Figures 2003. 2003, Atlanta: American Cancer Society American Cancer Society: Cancer Facts & Figures 2003. 2003, Atlanta: American Cancer Society
7.
8.
go back to reference Moore MW, Gasparini R: FISH as an effective diagnostic tool for the management of challenging melanocytic lesions. Diagn Pathol. 2011, 6: 76-10.1186/1746-1596-6-76.PubMedCentralCrossRefPubMed Moore MW, Gasparini R: FISH as an effective diagnostic tool for the management of challenging melanocytic lesions. Diagn Pathol. 2011, 6: 76-10.1186/1746-1596-6-76.PubMedCentralCrossRefPubMed
9.
go back to reference Schilling B, Bielefeld N, Sucker A, Hillen U, Zimmer L, Schadendorf D, Zeschnigk M, Griewank KG: Lack of SF3B1 R625 mutations in cutaneous melanoma. Diagn Pathol. 2013, 8: 87-10.1186/1746-1596-8-87.PubMedCentralCrossRefPubMed Schilling B, Bielefeld N, Sucker A, Hillen U, Zimmer L, Schadendorf D, Zeschnigk M, Griewank KG: Lack of SF3B1 R625 mutations in cutaneous melanoma. Diagn Pathol. 2013, 8: 87-10.1186/1746-1596-8-87.PubMedCentralCrossRefPubMed
10.
go back to reference Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK: Final version of AJCC melanoma staging and classification. J Clin Oncol. 2009, 2009 (27): 6199-6206.CrossRef Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK: Final version of AJCC melanoma staging and classification. J Clin Oncol. 2009, 2009 (27): 6199-6206.CrossRef
11.
go back to reference Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A: Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol. 2001, 19: 3622-PubMed Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A: Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol. 2001, 19: 3622-PubMed
12.
go back to reference Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlen M, Jirstrom K: High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malingnant melanoma. Diagn Pathol. 2012, 7: 82-10.1186/1746-1596-7-82.PubMedCentralCrossRefPubMed Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlen M, Jirstrom K: High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malingnant melanoma. Diagn Pathol. 2012, 7: 82-10.1186/1746-1596-7-82.PubMedCentralCrossRefPubMed
13.
go back to reference Enzinger FM: Clear-cell sarcoma of tendons and aponeuroses: an analysis of 21 cases. Cancer. 1965, 18: 1163-1174. 10.1002/1097-0142(196509)18:9<1163::AID-CNCR2820180916>3.0.CO;2-0.CrossRefPubMed Enzinger FM: Clear-cell sarcoma of tendons and aponeuroses: an analysis of 21 cases. Cancer. 1965, 18: 1163-1174. 10.1002/1097-0142(196509)18:9<1163::AID-CNCR2820180916>3.0.CO;2-0.CrossRefPubMed
14.
go back to reference Hocar O, Le Cesne A, Berissi S, Terrier P, Bonvalot S, Vanel D, Auperin A, Le Pechoux C, Bui B, Coindre JM, Robert C: Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract. 2012, 2012: 8- Hocar O, Le Cesne A, Berissi S, Terrier P, Bonvalot S, Vanel D, Auperin A, Le Pechoux C, Bui B, Coindre JM, Robert C: Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract. 2012, 2012: 8-
16.
go back to reference Morton DL: Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis. 2012, 29: 699-706. 10.1007/s10585-012-9503-3.PubMedCentralCrossRefPubMed Morton DL: Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis. 2012, 29: 699-706. 10.1007/s10585-012-9503-3.PubMedCentralCrossRefPubMed
17.
go back to reference Tsao H, Atkins MB, Sober AJ: Medical progress: management of cutaneous melanoma. NEJM. 2004, 351: 998-1012. 10.1056/NEJMra041245.CrossRefPubMed Tsao H, Atkins MB, Sober AJ: Medical progress: management of cutaneous melanoma. NEJM. 2004, 351: 998-1012. 10.1056/NEJMra041245.CrossRefPubMed
18.
go back to reference Patel RM, Downs-Kelly E, Weiss SW, Folpe AL, Tubbs RR, Tuthill RJ, Goldblum JR, Skacel M: Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. Mod Pathol. 2005, 18: 1585-1590.CrossRefPubMed Patel RM, Downs-Kelly E, Weiss SW, Folpe AL, Tubbs RR, Tuthill RJ, Goldblum JR, Skacel M: Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. Mod Pathol. 2005, 18: 1585-1590.CrossRefPubMed
Metadata
Title
Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma – a case report
Authors
Barrett Parker Wagner
Narendranath Epperla
Rafael Medina-Flores
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2013
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-8-192

Other articles of this Issue 1/2013

Diagnostic Pathology 1/2013 Go to the issue